Valuation: Aprea Therapeutics, Inc.

Market Cap 9.18M 8.02M 7.36M 6.87M 13.02M 874M 13.24M 88.65M 34.35M 428M 34.45M 33.7M 1.48B P/E 2026 *
-0.94x
P/E 2027 * -1.02x
Enterprise Value 9.18M 8.02M 7.36M 6.87M 13.02M 874M 13.24M 88.65M 34.35M 428M 34.45M 33.7M 1.48B EV / Sales 2026 *
17.2x
EV / Sales 2027 * 8.11x
Free-Float
79.15%
Yield 2026 *
-
Yield 2027 * -
05-15 Aprea Therapeutics - files for resale of up to 5.5 million shares by selling stockholders - SEC filing RE
05-14 Wedbush Adjusts Price Target on Aprea Therapeutics to $6 From $7, Maintains Outperform Rating MT
05-13 Aprea Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
05-07 Oppenheimer Initiates Aprea Therapeutics at Outperform With $5 Price Target MT
03-30 Aprea Therapeutics, Inc. announced that it has received $30.0204 million in funding from Soleus Capital LLC, Vestal Point Capital, LP, Squadron Capital Management Llc CI
03-30 Aprea Therapeutics, Inc. announced that it expects to receive $30.0204 million in funding from Soleus Capital LLC, Vestal Point Capital, LP, Squadron Capital Management Llc and other investors CI
03-30 Aprea Therapeutics Announces Positive Emerging Clinical Activity for Wee1 Inhibitor Apr-1051 with Confirmed Partial Response in Ongoing Phase 1 Acesot-1051 Trial CI
03-30 Aprea Therapeutics highlights positive emerging clinical activity for WEE1 inhibitor, APR-1051 RE
03-16 Aprea Therapeutics Q4 eps usd -0.32 RE
03-16 Aprea Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 CI
03-15 Aprea Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt CI
02-18 Aprea Therapeutics, Inc. Announces Additional Positive Clinical Activity for WEE1 Inhibitor, Apr-1051, Including Second Partial Response in Ongoing ACESOT-1051 Trial CI
02-18 Aprea Therapeutics announces additional positive clinical activity for Wee1 inhibitor, APR-1051 RE
1 day-0.55%
1 week-6.19%
Current month-7.64%
1 month-3.04%
3 months+3.58%
6 months-13.13%
Current year-13.13%
1 week 0.71
Extreme 0.71
0.82
1 month 0.65
Extreme 0.65
0.85
Current year 0.55
Extreme 0.548
1.49
1 year 0.55
Extreme 0.548
2.22
3 years 0.55
Extreme 0.548
8.85
5 years 0.55
Extreme 0.548
25.8
10 years 0.55
Extreme 0.548
25.8
Manager TitleAgeSince
Chief Executive Officer 58 2022-06-28
Director of Finance/CFO 62 2023-01-29
Corporate Officer/Principal 58 2023-10-31
Director TitleAgeSince
Director/Board Member 69 2014-12-31
Director/Board Member 64 2019-07-31
Chairman 64 2023-08-22
Date Insider Type Main position Quantity % Market Cap.
06-15Free

Chairman

15,690 0.1267%
06-15Free

Director

15,690 0.1267%
06-15Free

Director

15,690 0.1267%
Change 5-day change 1-year change 3-year change Capi.($)
-0.55%-6.19%-56.41%-76.48% 9.18M
+3.98%+5.55%+76.40%+132.19% 58.73B
-3.12%+3.48%+72.79%+94.67% 53.92B
+3.86%+8.38%-9.90%-9.62% 24.67B
+4.30%+6.82%+13.60%+428.91% 24.19B
+4.35%+13.20%+44.96%-1.84% 18.8B
+4.11%+8.89%+44.60%-27.36% 17.61B
+2.57%+16.74%+171.12%+355.99% 16.25B
+3.50%+4.92%+26.07%+192.26% 14.04B
+5.43%+17.75%+40.87% - 13.9B
Average +2.82%+7.35%+42.41%+120.97% 24.21B
Weighted average by Cap. +2.40%+7.21%+57.17%+135.72%

Financials

2026 *2027 *
Net sales 535K 467K 429K 400K 759K 50.93M 772K 5.17M 2M 24.98M 2.01M 1.97M 86.08M 1.13M 989K 908K 847K 1.61M 108M 1.63M 10.93M 4.24M 52.84M 4.25M 4.16M 182M
Net income -14.12M -12.33M -11.33M -10.56M -20.02M -1.34B -20.36M -136M -52.85M -659M -53M -51.85M -2.27B -16.4M -14.33M -13.16M -12.27M -23.27M -1.56B -23.66M -158M -61.41M -766M -61.59M -60.25M -2.64B
Net Debt - -
Logo Aprea Therapeutics, Inc.
Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality. The Company’s pipeline includes two clinical-stage synthetic lethality programs. Its lead programs are APR-1051, an oral, small-molecule inhibitor of WEE1 kinase, and ATRN-119, a small-molecule ATR inhibitor, both in clinical development for solid tumor indications. Its ATRN-119 is an oral small molecule inhibitor of ataxia telangiectasia and Rad3-related (ATR). The ATR kinase is a master regulator of Deoxyribonucleic Acid (DNA) damage response, with roles in cell cycle control and DNA repair following replication stress. It is evaluating potential combination opportunities within its pipeline, including research on the combination of ATRN-119 and APR-1051 that is supported by a Phase II SBIR grant from the National Cancer Institute. It also has an early-stage program, in the lead optimization stage, for an undisclosed DNA-damage response (DDR) target.
Employees
8
Date Price Change Volume
26-07-02 US$0.7410 -0.55% 131,524
26-07-01 US$0.7451 -7.13% 166,355
26-06-30 US$0.8023 -2.04% 107,530
26-06-29 US$0.8190 +3.67% 61,876
26-06-26 US$0.7900 +0.01% 40,536
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
0.7410USD
Average target price
4.300USD
Spread / Average Target
+480.30%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. APRE Stock